ECSP16012582A - Compuestos heterocíclicos y métodos de uso - Google Patents
Compuestos heterocíclicos y métodos de usoInfo
- Publication number
- ECSP16012582A ECSP16012582A ECIEPI201612582A ECPI201612582A ECSP16012582A EC SP16012582 A ECSP16012582 A EC SP16012582A EC IEPI201612582 A ECIEPI201612582 A EC IEPI201612582A EC PI201612582 A ECPI201612582 A EC PI201612582A EC SP16012582 A ECSP16012582 A EC SP16012582A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- heterocyclic compounds
- compounds
- conjunction
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente invención se refiere a compuestos y métodos para usar estos compuestos para tratar trastornos metabólicos y trastornos hiperproliferativos, que incluye la administración de los compuestos en conjunto con antagonistas del receptor hormonal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2816MU2013 | 2013-08-28 | ||
| IN3497MU2013 | 2013-11-04 | ||
| PCT/US2014/053215 WO2015031650A1 (en) | 2013-08-28 | 2014-08-28 | Heterocyclic compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP16012582A true ECSP16012582A (es) | 2018-09-30 |
Family
ID=52584081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201612582A ECSP16012582A (es) | 2013-08-28 | 2016-03-24 | Compuestos heterocíclicos y métodos de uso |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9670172B2 (es) |
| EP (1) | EP3038622B1 (es) |
| JP (2) | JP2017506618A (es) |
| KR (1) | KR20160067841A (es) |
| CN (1) | CN106029072A (es) |
| AU (1) | AU2014312245B2 (es) |
| CA (1) | CA2922346A1 (es) |
| CR (1) | CR20160136A (es) |
| DK (1) | DK3038622T3 (es) |
| EC (1) | ECSP16012582A (es) |
| ES (1) | ES2676585T3 (es) |
| HR (1) | HRP20181017T1 (es) |
| HU (1) | HUE039624T2 (es) |
| IL (1) | IL244268A0 (es) |
| LT (1) | LT3038622T (es) |
| MX (1) | MX2016002443A (es) |
| NO (1) | NO20160470A1 (es) |
| PH (1) | PH12016500382A1 (es) |
| PL (1) | PL3038622T3 (es) |
| PT (1) | PT3038622T (es) |
| RS (1) | RS57338B1 (es) |
| RU (1) | RU2016111138A (es) |
| SA (1) | SA516370641B1 (es) |
| SG (2) | SG11201601486TA (es) |
| SI (1) | SI3038622T1 (es) |
| TR (1) | TR201809185T4 (es) |
| UA (1) | UA116675C2 (es) |
| WO (1) | WO2015031650A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073826A1 (en) | 2014-11-07 | 2016-05-12 | Fgh Biotech, Inc. | Synthesis of fatostatin based polycyclic compounds |
| WO2016105491A1 (en) | 2014-12-23 | 2016-06-30 | Fgh Biotech | Compositions of fatostatin based heterocyclic compounds and uses thereof |
| US10183015B2 (en) | 2015-03-04 | 2019-01-22 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
| JP2018507235A (ja) | 2015-03-04 | 2018-03-15 | メディベイション テクノロジーズ エルエルシー | ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤 |
| CN105732355A (zh) * | 2016-04-07 | 2016-07-06 | 戊言医药科技（上海）有限公司 | 1-(5-氟-2-碘苯基)乙酮的制备方法 |
| MX2018013221A (es) | 2016-04-29 | 2019-06-24 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades. |
| CN110072861B (zh) * | 2016-09-07 | 2022-11-11 | Fgh生物科技公司 | 用于治疗疾病的二取代吡唑类化合物 |
| EP3676264A1 (en) * | 2017-08-28 | 2020-07-08 | Acurastem Inc. | Pikfyve kinase inhibitors |
| MX2020007956A (es) * | 2018-01-29 | 2021-01-08 | Capulus Therapeutics Llc | Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. |
| WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
| WO2021154735A1 (en) * | 2020-01-27 | 2021-08-05 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
| CN116041277A (zh) * | 2023-01-18 | 2023-05-02 | 中国药科大学 | 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3796764B2 (ja) * | 1995-01-25 | 2006-07-12 | コニカミノルタホールディングス株式会社 | 金属錯体化合物及び該化合物を用いた光記録媒体 |
| AU765072B2 (en) * | 1998-02-09 | 2003-09-11 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors |
| US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
| WO1999064389A1 (en) * | 1998-06-09 | 1999-12-16 | Alexandros Makriyannis | Inhibitors of the anandamide transporter as analgesic agents |
| CZ20022100A3 (cs) * | 1999-12-16 | 2002-09-11 | Schering Corporation | Substituované imidazolové deriváty a farmaceutický prostředek |
| TWI275589B (en) | 2000-06-22 | 2007-03-11 | Dow Agrosciences Llc | 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds |
| JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| US8168793B2 (en) | 2005-07-26 | 2012-05-01 | Portela & Ca., S.A. | Nitrocatechol derivatives as COMT inhibitors |
| EP1922068A4 (en) | 2005-08-16 | 2010-08-11 | Icagen Inc | INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS |
| US8229106B2 (en) | 2007-01-22 | 2012-07-24 | D.S.P. Group, Ltd. | Apparatus and methods for enhancement of speech |
| AU2008214095B2 (en) | 2007-02-02 | 2014-07-10 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| CA2748274A1 (en) * | 2008-12-30 | 2010-07-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| CA2786424A1 (en) | 2010-01-08 | 2011-07-14 | Ruga Corporation | Raf kinase inhibitors |
| WO2012084678A1 (en) | 2010-12-23 | 2012-06-28 | Syngenta Participations Ag | Novel imidazoles useful as plant fungicides |
| GB201116017D0 (en) | 2011-09-16 | 2011-10-26 | Univ Surrey | Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors |
| WO2013096642A1 (en) | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2014199164A1 (en) | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
| BR112015032540A2 (pt) | 2013-06-26 | 2017-07-25 | Baylor College Medicine | síndrome de rett e tratamentos para a mesma |
-
2014
- 2014-08-28 SG SG11201601486TA patent/SG11201601486TA/en unknown
- 2014-08-28 SI SI201430774T patent/SI3038622T1/en unknown
- 2014-08-28 MX MX2016002443A patent/MX2016002443A/es unknown
- 2014-08-28 CR CR20160136A patent/CR20160136A/es unknown
- 2014-08-28 CN CN201480054063.3A patent/CN106029072A/zh active Pending
- 2014-08-28 RS RS20180723A patent/RS57338B1/sr unknown
- 2014-08-28 TR TR2018/09185T patent/TR201809185T4/tr unknown
- 2014-08-28 RU RU2016111138A patent/RU2016111138A/ru not_active Application Discontinuation
- 2014-08-28 ES ES14839213.7T patent/ES2676585T3/es active Active
- 2014-08-28 PT PT148392137T patent/PT3038622T/pt unknown
- 2014-08-28 WO PCT/US2014/053215 patent/WO2015031650A1/en active Application Filing
- 2014-08-28 JP JP2016537857A patent/JP2017506618A/ja active Pending
- 2014-08-28 AU AU2014312245A patent/AU2014312245B2/en not_active Ceased
- 2014-08-28 KR KR1020167007463A patent/KR20160067841A/ko not_active Application Discontinuation
- 2014-08-28 LT LTEP14839213.7T patent/LT3038622T/lt unknown
- 2014-08-28 HU HUE14839213A patent/HUE039624T2/hu unknown
- 2014-08-28 UA UAA201603203A patent/UA116675C2/uk unknown
- 2014-08-28 SG SG10201806370QA patent/SG10201806370QA/en unknown
- 2014-08-28 PL PL14839213T patent/PL3038622T3/pl unknown
- 2014-08-28 DK DK14839213.7T patent/DK3038622T3/en active
- 2014-08-28 EP EP14839213.7A patent/EP3038622B1/en active Active
- 2014-08-28 CA CA2922346A patent/CA2922346A1/en not_active Abandoned
- 2014-08-28 US US14/471,977 patent/US9670172B2/en not_active Expired - Fee Related
-
2016
- 2016-02-24 IL IL244268A patent/IL244268A0/en unknown
- 2016-02-26 PH PH12016500382A patent/PH12016500382A1/en unknown
- 2016-02-28 SA SA516370641A patent/SA516370641B1/ar unknown
- 2016-03-18 NO NO20160470A patent/NO20160470A1/en not_active Application Discontinuation
- 2016-03-24 EC ECIEPI201612582A patent/ECSP16012582A/es unknown
-
2018
- 2018-07-02 HR HRP20181017TT patent/HRP20181017T1/hr unknown
-
2019
- 2019-03-20 JP JP2019052536A patent/JP2019089854A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16012582A (es) | Compuestos heterocíclicos y métodos de uso | |
| TR201902516T4 (tr) | Glukagon-glp-1-gıp üçlü agonist bileşikleri. | |
| LTPA2021003I1 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su KIT | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UA118558C2 (uk) | Пептидна сполука | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| CO2017002159A2 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| BR112015021732A2 (pt) | dispositivo para uso terapêutico | |
| BR112015030387A8 (pt) | compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| CR20160002A (es) | Formulación estable líquida de etelcalcetide (amg 461) | |
| BR112018072020A2 (pt) | semaglutida em condições cardiovasculares | |
| GT201400153A (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
| DOP2015000176A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CL2017000587A1 (es) | Derivados de tetrahidroquinolina como inhibidores de bromodominio | |
| CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
| CL2016000325A1 (es) | Antagonistas de vía para tratar trastornos del sueño por cambio de fase | |
| CL2015002666A1 (es) | Formas de dosificación sólidas de antiemético de liberación prolongada | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| CL2016000397A1 (es) | Tratamiento contra el cáncer | |
| CL2016000171A1 (es) | Formulación de metaxalona. | |
| CL2012003253A1 (es) | Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico. |